Real life data with a six months follow-up from dietary interventions, biologic therapy and functional endoscopic surgery (FESS) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Clemens Stihl, Tobias Dombrowski, Bernhard G Weiss, Jennifer L Spiegel, Anne Guertler, Friedrich Ihler, Saskia Freytag, Ines Bertlich, Moritz Gröger, Eva Oppel, Mattis Bertlich

Journal: Medicine 2025;104(32):e43714

PMID: 40797394

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory condition associated with significant morbidity. While established treatments such as functional endoscopic sinus surgery (FESS) and biologic therapy have demonstrated efficacy, they come with limitations, including cost, accessibility, and patient adherence. Growing evidence suggests that dietary factors, particularly arachidonic acid and salicylic acid, influence inflammatory pathways relevant to CRSwNP, yet real-world data on dietary interventions remain scarce. This retrospective study evaluates the mid-term effects of a structured dietary intervention in patients with CRSwNP who were either unwilling to undergo FESS or biologic therapy. The outcomes were compared to those of patients receiving either FESS or dupilumab. The dietary intervention was based on the avoidance of arachidonic acid and salicylates, an increase in fiber-rich foods, and the exclusion of nonsteroidal anti-inflammatory drugs. A total of 45 patients (mean age 46.5 ± 14.1 years; 25 female and 20 male) were included, with 15 undergoing dietary intervention, 15 FESS, and 15 dupilumab therapy. Disease burden was assessed using the sino-nasal outcome test (SNOT-22), visual analog scale, endoscopy scoring, and the brief smell identification test at baseline and follow-ups at 3 and 6 months. Patients undergoing dietary intervention experienced significant symptom improvement, although the response was less pronounced compared to FESS or dupilumab. At 6 months, mean SNOT-22 scores improved from 69.8 to 19.7 (FESS), 58.0 to 16.1 (dupilumab), and 39.5 to 24.2 (dietary intervention). visual analog scale scores showed a similar trend, decreasing from 8.4 to 2.9 (FESS), 8.1 to 2.2 (dupilumab), and 5.6 to 3.5 (dietary). While objective olfactory scores (brief smell identification test) improved in all groups, it was less pronounced in the dietary intervention group. Notably, patients in the dietary intervention group reported continued adherence and tolerability of the intervention. Dietary intervention may serve as a viable adjunct for CRSwNP patients who are unable or unwilling to undergo surgery or biologics. Despite lower efficacy, its safety and accessibility merit further investigation.

Copyright © 2025 the Author(s). Published by Wolters Kluwer Health, Inc.

Address: Department of Otorhinolaryngology, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Federal Republic of Germany.; Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center, Georg-August University of Göttingen, Göttingen, Germany.; Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, Munich, Germany.; Department of Otorhinolaryngology, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Federal Republic of Germany.; Department of Otorhinolaryngology, Head and Neck Surgery, Greifswald University Medicine, Greifswald, Federal Republic of Germany.; Epigenetics and Genomics, Harry Perkins Institute of Medical Research, Nedlands, WA, Australia.; Department of Dermatology, Venerology and Allergology, University Medical Center, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.; Department of Otorhinolaryngology, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Federal Republic of Germany.; Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, Munich, Germany.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.